Supriya Lifescience Ltd
Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.[1]
- Market Cap ₹ 5,481 Cr.
- Current Price ₹ 680
- High / Low ₹ 842 / 368
- Stock P/E 29.2
- Book Value ₹ 124
- Dividend Yield 0.12 %
- ROCE 27.4 %
- ROE 20.7 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|
184 | 213 | 278 | 312 | 391 | 530 | 461 | 570 | 696 | |
166 | 191 | 213 | 213 | 218 | 316 | 332 | 394 | 436 | |
Operating Profit | 17 | 22 | 65 | 98 | 173 | 214 | 129 | 176 | 261 |
OPM % | 9% | 10% | 23% | 32% | 44% | 40% | 28% | 31% | 37% |
7 | 9 | 8 | 11 | 5 | 8 | 9 | 11 | 10 | |
Interest | 12 | 11 | 10 | 7 | 4 | 4 | 3 | 5 | 2 |
Depreciation | 5 | 5 | 5 | 6 | 7 | 10 | 12 | 16 | 20 |
Profit before tax | 8 | 14 | 57 | 96 | 167 | 207 | 123 | 166 | 248 |
Tax % | 30% | 40% | 31% | 24% | 26% | 27% | 27% | 28% | 24% |
6 | 9 | 39 | 73 | 124 | 152 | 90 | 119 | 188 | |
EPS in Rs | 3.87 | 5.96 | 26.93 | 50.11 | 16.89 | 18.86 | 11.17 | 14.80 | 23.35 |
Dividend Payout % | 0% | 0% | 0% | 20% | 3% | 3% | 5% | 5% | 4% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 17% |
3 Years: | 10% |
TTM: | 22% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 21% |
3 Years: | 7% |
TTM: | 58% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 25% |
1 Year: | 82% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 23% |
3 Years: | 17% |
Last Year: | 21% |
Balance Sheet
Figures in Rs. Crores
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|
Equity Capital | 15 | 15 | 15 | 15 | 15 | 16 | 16 | 16 | 16 |
Reserves | 31 | 40 | 79 | 134 | 254 | 600 | 683 | 799 | 981 |
140 | 130 | 90 | 82 | 72 | 27 | 22 | 5 | 5 | |
55 | 60 | 69 | 105 | 105 | 92 | 98 | 100 | 110 | |
Total Liabilities | 241 | 245 | 253 | 336 | 445 | 735 | 820 | 921 | 1,112 |
89 | 91 | 85 | 99 | 100 | 190 | 262 | 310 | 453 | |
CWIP | 36 | 34 | 35 | 40 | 79 | 43 | 68 | 149 | 148 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 64 | 63 |
117 | 120 | 133 | 197 | 267 | 502 | 466 | 398 | 448 | |
Total Assets | 241 | 245 | 253 | 336 | 445 | 735 | 820 | 921 | 1,112 |
Cash Flows
Figures in Rs. Crores
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|
27 | 28 | 49 | 117 | 76 | 49 | 64 | 113 | 165 | |
-27 | -5 | 5 | -25 | -47 | -60 | -124 | -174 | -152 | |
-2 | -20 | -50 | -29 | -15 | 150 | -10 | -22 | -8 | |
Net Cash Flow | -2 | 3 | 4 | 62 | 15 | 139 | -70 | -83 | 4 |
Ratios
Figures in Rs. Crores
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|
Debtor Days | 99 | 92 | 79 | 60 | 69 | 79 | 67 | 71 | 70 |
Inventory Days | 113 | 85 | 77 | 130 | 206 | 172 | 234 | 140 | 205 |
Days Payable | 121 | 112 | 110 | 130 | 145 | 91 | 130 | 98 | 129 |
Cash Conversion Cycle | 91 | 64 | 45 | 61 | 130 | 160 | 171 | 114 | 146 |
Working Capital Days | 119 | 97 | 96 | 49 | 94 | 132 | 181 | 158 | 145 |
ROCE % | 14% | 37% | 50% | 60% | 43% | 19% | 22% | 27% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
31 May - Earnings Call Transcript for the Earnings call held on May 28, 2025 with respect to Audited Financial Results of the Company for the quarter and …
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
28 May - Annual Secretarial Compliance Report for FY 2024-25 confirms full regulatory compliance with no violations.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
28 May - Audio recording of Q4 and FY25 earnings call available on company website.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
28 May - Newspaper Publication of Audited Financial Results for March 31, 2025.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
28 May - FY25 revenue Rs 696.48 Cr (+22%), PAT Rs 187.96 Cr (+57.8%), Q4 PAT up 38.4%.
Annual reports
Concalls
-
May 2025Transcript PPT REC
-
Jan 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT REC
-
Jun 2024Transcript PPT REC
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT REC
-
Jun 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
May 2022TranscriptNotesPPT
-
Feb 2022TranscriptPPT
-
Jan 2022Transcript PPT
Niche Products Offerings[1]
Supriya Lifescience Ltd. has a niche product basket of 40+ APIs and is a global leader in Anti-histamines, anti-allergy, Vitamins, Anti-Asthmatics, & Anesthetics. They utilize a backward-integrated model for 15 products and possess the ability to handle complex chemistries and controlled substances.